Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):969-72. doi: 10.1097/MEG.0b013e328328f3ec.

Abstract

Objectives: The effect of light-to-moderate alcohol consumption (LMAC) in nonalcoholic fatty liver disease (NAFLD) remains a controversial subject. The aim of this study was to evaluate the relationship between LMAC and the severity of NAFLD in morbidly obese patients.

Methods: We studied 132 patients undergoing liver biopsy during bariatric surgery. The patients were divided into three groups: G1: alcohol intake greater than 20 g/day and less than 40 g/day; G2: alcohol intake less than 20 g/day; G3: no alcohol intake. Insulin resistance was defined by the Homeostasis Model Assessment (>3). NAFLD was classified according to the Matteoni types: type I: steatosis alone; type II: steatosis with inflammation; types III-IV: steatosis with ballooning and/or fibrosis.

Results: The mean age was 37.3+/-11 years. Sixty-three percent were females and body mass index was 43.9+/-5.6 kg/m. G1, G2, and G3 included 19, 56, and 57 patients, respectively. Histological diagnoses classified by levels of alcohol were: G1: 10.5% normal liver, 89.5% type III or IV; G2: 10.7% normal liver, 1.8% type I or II, and 87.5% grade III or IV; G3: 10.5% normal liver, 3.5% type I or II, and 86% type III or IV (one had cirrhosis). The presence of IR was similar in moderate and no alcohol consumption (81.3 and 78.7%) but significantly less in the light consumption group (54%, P<0.05).

Conclusion: The results suggest that LMAC may have a protection effect against IR in severely obese patients. However, it had no impact on the severity of activity and stage of liver disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alcohol Drinking / adverse effects*
  • Bariatric Surgery
  • Body Mass Index
  • Cross-Sectional Studies
  • Fatty Liver / drug therapy
  • Fatty Liver / pathology*
  • Female
  • Humans
  • Insulin Resistance / physiology
  • Male
  • Middle Aged
  • Obesity, Morbid / complications*
  • Obesity, Morbid / drug therapy
  • Young Adult